Iterum Stock Based Compensation vs Begin Period Cash Flow Analysis

ITRM Stock

USD 1.80 0.18 9.09%

Iterum Therapeutics financial indicator trend analysis is infinitely more than just investigating Iterum Therapeutics PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iterum Therapeutics PLC is a good investment. Please check the relationship between Iterum Therapeutics Stock Based Compensation and its Begin Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iterum Therapeutics PLC Stock Based Compensation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Iterum Therapeutics' Stock Based Compensation and Begin Period Cash Flow is 0.18. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Iterum Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Iterum Therapeutics' Stock Based Compensation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Iterum Therapeutics PLC are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Stock Based Compensation i.e., Iterum Therapeutics' Stock Based Compensation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Iterum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Iterum Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 14th of December 2024, Sales General And Administrative To Revenue is likely to grow to 288.20, while Tax Provision is likely to drop about 521.7 K.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	2.1M	1.8M	1.7M	969.1K
Income Tax Expense	705K	301K	613K	527.3K

Reconciled Depreciation Income Tax Expense

Iterum Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Preferred Stock Total Equity	Total Current Assets	Common Stock	Other Liab
Total Assets		0.11	-0.13	0.63	0.58	-0.02	-0.29	-0.09	0.53	0.38	0.27	0.23	0.92	0.58	0.28	0.55	0.86	0.34	0.49	0.27	0.48	0.23	0.5	0.92	0.59	0.33
Other Current Liab	0.11		0.52	-0.57	-0.57	0.67	-0.47	-0.16	-0.2	0.53	0.52	0.8	0.0	0.41	0.61	0.25	0.12	0.65	0.56	0.43	0.39	0.82	0.47	-0.01	0.37	0.24
Total Current Liabilities	-0.13	0.52		-0.71	-0.7	0.57	-0.36	0.72	-0.51	0.8	0.84	0.77	-0.33	0.59	0.33	0.03	-0.14	0.74	0.53	0.79	0.23	0.75	0.52	-0.35	0.09	0.07
Total Stockholder Equity	0.63	-0.57	-0.71		0.95	-0.67	0.33	-0.34	0.72	-0.33	-0.4	-0.49	0.71	-0.09	-0.36	0.16	0.5	-0.48	-0.27	-0.25	-0.13	-0.6	-0.17	0.73	0.12	-0.08
Net Tangible Assets	0.58	-0.57	-0.7	0.95		-0.55	0.16	-0.31	0.58	-0.45	-0.52	-0.59	0.72	-0.21	-0.2	0.13	0.55	-0.48	-0.16	-0.28	0.01	-0.59	-0.07	0.74	0.08	0.12
Net Debt	-0.02	0.67	0.57	-0.67	-0.55		-0.87	0.28	-0.73	0.4	0.37	0.47	-0.04	0.39	0.87	0.29	0.3	0.77	0.79	0.31	0.76	0.84	0.74	-0.04	0.32	0.69
Retained Earnings	-0.29	-0.47	-0.36	0.33	0.16	-0.87		-0.24	0.46	-0.31	-0.24	-0.26	-0.34	-0.39	-0.97	-0.45	-0.59	-0.76	-0.9	-0.18	-0.96	-0.74	-0.78	-0.32	-0.46	-0.94
Accounts Payable	-0.09	-0.16	0.72	-0.34	-0.31	0.28	-0.24		-0.46	0.56	0.59	0.26	-0.25	0.44	0.07	-0.1	-0.06	0.48	0.37	0.58	0.2	0.34	0.43	-0.26	-0.12	0.08
Cash	0.53	-0.2	-0.51	0.72	0.58	-0.73	0.46	-0.46		-0.06	-0.09	-0.1	0.51	-0.03	-0.4	0.07	0.13	-0.31	-0.3	-0.15	-0.29	-0.38	-0.38	0.49	0.11	-0.33
Non Current Assets Total	0.38	0.53	0.8	-0.33	-0.45	0.4	-0.31	0.56	-0.06		0.99	0.9	0.08	0.89	0.29	0.3	0.18	0.84	0.62	0.8	0.33	0.78	0.58	0.06	0.38	0.02
Non Currrent Assets Other	0.27	0.52	0.84	-0.4	-0.52	0.37	-0.24	0.59	-0.09	0.99		0.9	-0.03	0.83	0.22	0.19	0.06	0.8	0.55	0.82	0.24	0.76	0.52	-0.06	0.28	-0.06
Other Assets	0.23	0.8	0.77	-0.49	-0.59	0.47	-0.26	0.26	-0.1	0.9	0.9		-0.05	0.78	0.33	0.33	0.05	0.75	0.53	0.71	0.23	0.82	0.49	-0.07	0.44	-0.05
Cash And Short Term Investments	0.92	0.0	-0.33	0.71	0.72	-0.04	-0.34	-0.25	0.51	0.08	-0.03	-0.05		0.32	0.34	0.51	0.91	0.19	0.38	0.06	0.48	0.08	0.38	1.0	0.52	0.48
Net Receivables	0.58	0.41	0.59	-0.09	-0.21	0.39	-0.39	0.44	-0.03	0.89	0.83	0.78	0.32		0.35	0.66	0.46	0.76	0.63	0.59	0.46	0.69	0.63	0.31	0.71	0.18
Common Stock Total Equity	0.28	0.61	0.33	-0.36	-0.2	0.87	-0.97	0.07	-0.4	0.29	0.22	0.33	0.34	0.35		0.47	0.56	0.74	0.87	0.15	0.92	0.77	0.73	0.32	0.49	0.91
Common Stock Shares Outstanding	0.55	0.25	0.03	0.16	0.13	0.29	-0.45	-0.1	0.07	0.3	0.19	0.33	0.51	0.66	0.47		0.59	0.4	0.45	-0.11	0.54	0.37	0.36	0.5	0.99	0.47
Short Term Investments	0.86	0.12	-0.14	0.5	0.55	0.3	-0.59	-0.06	0.13	0.18	0.06	0.05	0.91	0.46	0.56	0.59		0.38	0.62	0.16	0.71	0.29	0.67	0.91	0.59	0.67
Non Current Liabilities Total	0.34	0.65	0.74	-0.48	-0.48	0.77	-0.76	0.48	-0.31	0.84	0.8	0.75	0.19	0.76	0.74	0.4	0.38		0.87	0.62	0.71	0.96	0.75	0.17	0.46	0.52
Capital Surpluse	0.49	0.56	0.53	-0.27	-0.16	0.79	-0.9	0.37	-0.3	0.62	0.55	0.53	0.38	0.63	0.87	0.45	0.62	0.87		0.48	0.92	0.85	0.93	0.37	0.5	0.75
Other Current Assets	0.27	0.43	0.79	-0.25	-0.28	0.31	-0.18	0.58	-0.15	0.8	0.82	0.71	0.06	0.59	0.15	-0.11	0.16	0.62	0.48		0.14	0.59	0.6	0.06	-0.02	-0.07
Other Stockholder Equity	0.48	0.39	0.23	-0.13	0.01	0.76	-0.96	0.2	-0.29	0.33	0.24	0.23	0.48	0.46	0.92	0.54	0.71	0.71	0.92	0.14		0.67	0.82	0.46	0.54	0.91
Total Liab	0.23	0.82	0.75	-0.6	-0.59	0.84	-0.74	0.34	-0.38	0.78	0.76	0.82	0.08	0.69	0.77	0.37	0.29	0.96	0.85	0.59	0.67		0.73	0.06	0.45	0.48
Preferred Stock Total Equity	0.5	0.47	0.52	-0.17	-0.07	0.74	-0.78	0.43	-0.38	0.58	0.52	0.49	0.38	0.63	0.73	0.36	0.67	0.75	0.93	0.6	0.82	0.73		0.38	0.4	0.63
Total Current Assets	0.92	-0.01	-0.35	0.73	0.74	-0.04	-0.32	-0.26	0.49	0.06	-0.06	-0.07	1.0	0.31	0.32	0.5	0.91	0.17	0.37	0.06	0.46	0.06	0.38		0.51	0.47
Common Stock	0.59	0.37	0.09	0.12	0.08	0.32	-0.46	-0.12	0.11	0.38	0.28	0.44	0.52	0.71	0.49	0.99	0.59	0.46	0.5	-0.02	0.54	0.45	0.4	0.51		0.44
Other Liab	0.33	0.24	0.07	-0.08	0.12	0.69	-0.94	0.08	-0.33	0.02	-0.06	-0.05	0.48	0.18	0.91	0.47	0.67	0.52	0.75	-0.07	0.91	0.48	0.63	0.47	0.44

Click cells to compare fundamentals

Iterum Therapeutics Account Relationship Matchups

Iterum Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.8M	32.8M	91.5M	66.8M	26.3M	24.9M
Other Current Liab	3.0M	34.3M	10.2M	6.3M	8.5M	10.5M
Total Current Liabilities	37.0M	28.9M	6.1M	196K	13.5M	15.0M
Total Stockholder Equity	(26.2M)	(50.6M)	50.2M	28.0M	(6.4M)	(6.1M)
Net Tangible Assets	(26.2M)	(50.6M)	46.8M	26.3M	23.7M	14.9M
Net Debt	2.8M	21.3M	(2.5M)	7.4M	12.9M	13.5M
Retained Earnings	(234.9M)	(286.9M)	(378.5M)	(422.9M)	(461.3M)	(438.2M)
Accounts Payable	15.5M	816K	878K	2.8M	5.0M	3.4M
Cash	4.8M	14.5M	27.4M	21.1M	6.1M	5.8M
Non Current Assets Total	21.0M	18.3M	10.2M	6.0M	663K	629.9K
Non Currrent Assets Other	20.3M	17.6M	6.6M	4.2M	63K	59.9K
Other Assets	6.3M	10.9M	4.7M	831K	955.7K	907.9K
Cash And Short Term Investments	4.8M	14.5M	81.3M	60.8M	23.9M	45.9M
Net Receivables	1.1M	865K	1.2M	513K	233K	221.4K
Common Stock Shares Outstanding	14.5M	24.0M	163.4M	12.2M	13.0M	12.3M
Short Term Investments	1.1K	2.4M	53.9M	39.7M	17.9M	25.4M
Liabilities And Stockholders Equity	25.8M	32.8M	91.5M	66.8M	26.3M	24.9M
Non Current Liabilities Total	52.0M	54.5M	35.2M	38.6M	19.1M	31.1M
Capital Surpluse	94.2M	203.3M	208.5M	235.9M	271.3M	173.8M
Other Current Assets	6.9M	6.0M	717K	1.1M	1.4M	2.9M
Other Stockholder Equity	208.5M	235.9M	426.9M	451.2M	454.8M	291.9M
Total Liab	52.0M	83.4M	41.3M	38.8M	32.7M	39.3M
Total Current Assets	4.8M	14.5M	81.3M	60.8M	25.6M	47.0M
Common Stock	149K	494K	1.8M	126K	135K	128.3K
Property Plant And Equipment Net	572K	421K	91K	69K	600K	365.7K
Net Invested Capital	(12.8M)	(8.2M)	24.9M	56.5M	12.6M	22.6M
Property Plant And Equipment Gross	7.7M	421K	377K	353K	366K	347.7K
Non Current Liabilities Other	7.4M	19.2M	10.3M	1.3M	188K	178.6K
Net Working Capital	(25.3M)	(20.2M)	75.3M	53.4M	12.1M	11.5M
Property Plant Equipment	7.7M	421K	91K	1.8M	1.7M	1.5M
Short Long Term Debt Total	13.4M	35.9M	24.9M	28.5M	19.0M	24.9M
Current Deferred Revenue	12.7M	(7.3M)	(2.5M)	(332K)	(298.8K)	(283.9K)
Long Term Debt	7.6M	22.5M	24.9M	28.5M	19.0M	21.2M
Inventory	(8.0M)	(3.7M)	(3.1M)	(1.9M)	(2.1M)	(2.2M)
Capital Stock	149K	494K	1.8M	126K	135K	128.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:

How To Invest In Iterum

Details

Is Iterum Stock a good investment?

Details

What is Iterum Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.76)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.73)

Return On Equity

(5.56)

The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iterum Stock Based Compensation vs Begin Period Cash Flow Analysis

Stock Based Compensation vs Begin Period Cash Flow

Stock Based Compensation vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Begin Period Cash Flow

Iterum Therapeutics fundamental ratios Correlations

Iterum Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iterum Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Common Stock	+ 0.99	Common Stock Shares Outstanding
Total Liab	+ 0.96	Non Current Liabilities Total
Net Tangible Assets	+ 0.95	Total Stockholder Equity
Preferred Stock Total Equity	+ 0.93	Capital Surpluse

Common Stock Total Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Other Liab	- 0.94	Retained Earnings
Capital Surpluse	- 0.9	Retained Earnings
Retained Earnings	- 0.87	Net Debt
Preferred Stock Total Equity	- 0.78	Retained Earnings